Show simple item record

dc.contributor.authorBattisti, NML
dc.contributor.authorReed, MWR
dc.contributor.authorHerbert, E
dc.contributor.authorMorgan, JL
dc.contributor.authorCollins, KA
dc.contributor.authorWard, SE
dc.contributor.authorHolmes, GR
dc.contributor.authorBradburn, M
dc.contributor.authorWalters, SJ
dc.contributor.authorBurton, M
dc.contributor.authorLifford, K
dc.contributor.authorEdwards, A
dc.contributor.authorRobinson, TG
dc.contributor.authorMartin, C
dc.contributor.authorChater, T
dc.contributor.authorPemberton, KJ
dc.contributor.authorShrestha, A
dc.contributor.authorBrennan, A
dc.contributor.authorCheung, KL
dc.contributor.authorTodd, A
dc.contributor.authorAudisio, RA
dc.contributor.authorWright, J
dc.contributor.authorSimcock, R
dc.contributor.authorGreen, T
dc.contributor.authorRevell, D
dc.contributor.authorGath, J
dc.contributor.authorHorgan, K
dc.contributor.authorHolcombe, C
dc.contributor.authorWinter, MC
dc.contributor.authorNaik, J
dc.contributor.authorParmeshwar, R
dc.contributor.authorGosney, MA
dc.contributor.authorHatton, MQ
dc.contributor.authorThompson, AM
dc.contributor.authorWyld, L
dc.contributor.authorRing, A
dc.contributor.authorAge Gap TMG
dc.date.accessioned2021-03-23T09:41:19Z
dc.date.available2021-03-23T09:41:19Z
dc.identifier.citationEuropean journal of cancer (Oxford, England : 1990), 2021, 144 pp. 269 - 280
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4425
dc.identifier.eissn1879-0852
dc.identifier.eissn1879-0852en_US
dc.identifier.doi10.1016/j.ejca.2020.11.022
dc.identifier.doi10.1016/j.ejca.2020.11.022en_US
dc.description.abstractIntroduction Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality of life in older patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate its effect on quality of life in older patients enrolled in the Bridging the Age Gap study.Materials and methods A prospective, multicentre, observational study of EBC patients ≥70 years old was conducted in 2013-2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse events were recorded. Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaires (EORTC-QLQ) C30, BR23 and ELD 15 plus the Euroqol-5D (eq-5d) over 24 months and analysed at each time point using baseline adjusted linear regression analysis and propensity score-matching.Results Three thousand and four hundred sixteen patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18-24 months in unmatched and matched cohorts.Conclusions The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 months but resolves by 18 months, which is crucial to inform decision-making for older patients contemplating chemotherapy.Trial registration number isrctn 46099296.
dc.formatPrint-Electronic
dc.format.extent269 - 280
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAge Gap TMG
dc.titleBridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer.
dc.typeJournal Article
dcterms.dateAccepted2020-11-14
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.ejca.2020.11.022
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean journal of cancer (Oxford, England : 1990)
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.publication-statusPublished
pubs.volume144en_US
pubs.embargo.termsNo embargo
icr.researchteamBreast Cancer Clinical Research
icr.researchteamBreast Cancer Clinical Researchen_US
dc.contributor.icrauthorBattisti, Nicoloen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/